{"id":1011,"date":"2026-07-02T19:45:22","date_gmt":"2026-07-02T19:45:22","guid":{"rendered":"https:\/\/menteymanzana.com\/?p=1011"},"modified":"2026-07-02T19:45:22","modified_gmt":"2026-07-02T19:45:22","slug":"glucosamina-la-paradoja-del-alzheimer","status":"publish","type":"post","link":"https:\/\/menteymanzana.com\/en\/glucosamina-la-paradoja-del-alzheimer\/","title":{"rendered":"GLUCOSAMINE: THE ALZHEIMER&#039;S PARADOX"},"content":{"rendered":"<style> \/* === Ocultar elementos del tema para layout custom === *\/ body.postid-1011>.wp-site-blocks>main.wp-block-group{display:none!important} body.postid-1011 .wp-site-blocks>.wp-block-group.has-global-padding{padding-top:0!important} body.postid-1011 .wp-site-blocks>.wp-block-group>.wp-block-group:first-child{padding-top:0!important;margin-top:0!important} body.postid-1011 .entry-title{display:none!important} body.postid-1011 .wp-block-post-title{display:none!important} body.postid-1011 main{padding-top:0!important} body.postid-1011 .post-thumbnail,body.postid-1011 .wp-block-post-featured-image{display:none!important;margin-top:0!important;margin-bottom:0!important} body.postid-1011 article>*:first-child,body.postid-1011 .entry-content{margin-top:0!important;padding-top:0!important} \/* === T\u00edtulo custom === *\/ body.postid-1011 h1.mm-custom-title{color:#fff!important;font-size:2.4em;line-height:1.2;margin:0.6em 0 0.4em;text-align:center;font-weight:800;letter-spacing:-.01em} body.postid-1011 h1.mm-custom-title .accent{color:#c6f432} body.postid-1011 .mm-subtitle{color:#c6f432;text-align:center;font-size:1.05em;font-weight:600;letter-spacing:.04em;text-transform:uppercase;margin:0 0 1.8em} \/* === Hero === *\/ body.postid-1011 .mm-hero{margin:0 0 1.5em!important} body.postid-1011 .mm-hero img{width:100%;max-height:480px;object-fit:cover;display:block;border-radius:6px} \/* === Contenido === *\/ body.postid-1011 .mm-content h2{color:#c6f432!important;font-size:1.55em;margin:1.8em 0 .7em;clear:both;border-bottom:2px solid rgba(198,244,50,.25);padding-bottom:.35em} body.postid-1011 .mm-content h3{color:#fff!important;font-size:1.2em;margin:1.2em 0 .55em;clear:both;width:100%} body.postid-1011 .mm-content p{color:#e8e8e8;line-height:1.7;margin:0 0 1em;font-size:1rem} body.postid-1011 .mm-content strong{color:#fff} body.postid-1011 .mm-content em{color:#cccccc} body.postid-1011 .mm-content ul{color:#e8e8e8;margin:.8rem 0 1.2rem 1.25rem;line-height:1.7} body.postid-1011 .mm-content ul li{margin-bottom:.4rem} \/* === Im\u00e1genes de secci\u00f3n === *\/ body.postid-1011 .mm-content figure.mm-section-img{margin:1.4em 0 1.6em;border-radius:6px;overflow:hidden;border:1px solid rgba(198,244,50,.18);box-shadow:0 6px 18px rgba(0,0,0,.35)} body.postid-1011 .mm-content figure.mm-section-img img{width:100%;height:auto;display:block} body.postid-1011 .mm-content figure.mm-section-img figcaption{background:#1a1a1a;color:#c6f432;padding:.6rem .9rem;font-size:.85rem;font-style:italic;text-align:center;border-top:1px solid rgba(198,244,50,.2)} \/* === Callout (puntos clave) === *\/ body.postid-1011 .mm-callout{background:rgba(198,244,50,.06);border-left:3px solid #c6f432;border-radius:4px;padding:1em 1.25em;margin:1.5em 0;color:#e8e8e8} body.postid-1011 .mm-callout strong{color:#c6f432} \/* === Disclaimer (notas editoriales sensibles) === *\/ body.postid-1011 .mm-disclaimer{background:rgba(244,211,94,.06);border:1px solid rgba(244,211,94,.3);border-radius:6px;padding:1em 1.25em;margin:1.2em 0 1.6em;color:#f4d35e;font-size:.93em} body.postid-1011 .mm-disclaimer strong{color:#ffe680} \/* === Blockquote === *\/ body.postid-1011 .mm-content blockquote{background:#1a1a1a;color:#fff;padding:1.1rem 1.5rem;border-radius:6px;margin:1.4rem 0;font-size:1.05rem;border-left:4px solid #c6f432} body.postid-1011 .mm-content blockquote .mm-source{display:block;margin-top:.6rem;font-size:.83rem;color:#c6f432;font-weight:600} \/* === Tablas === *\/ body.postid-1011 .mm-content table{width:100%;border-collapse:collapse;margin:1.2rem 0;font-size:.88rem;background:#161616;border-radius:6px;overflow:hidden;box-shadow:0 4px 12px rgba(0,0,0,.3)} body.postid-1011 .mm-content table th{background:#c6f432;color:#0a0a0a;padding:.65rem .8rem;text-align:left;font-weight:800;font-size:.82rem;text-transform:uppercase;letter-spacing:.03em} body.postid-1011 .mm-content table td{padding:.6rem .8rem;border-bottom:1px solid rgba(255,255,255,.08);vertical-align:top;color:#d8d8d8} body.postid-1011 .mm-content table tr:nth-child(even) td{background:rgba(255,255,255,.025)} body.postid-1011 .mm-content table strong{color:#c6f432} \/* === Keyfig (datos destacados inline) === *\/ body.postid-1011 .mm-keyfig{display:inline-block;background:#c6f432;color:#0a0a0a;font-weight:800;padding:.1rem .5rem;border-radius:3px;font-size:.92em;white-space:nowrap} \/* === Referencias === *\/ body.postid-1011 .mm-refs{margin-top:2em;padding:1.3em 1.6em;background:rgba(198,244,50,.05);border-left:3px solid #c6f432;border-radius:4px} body.postid-1011 .mm-refs h3{color:#c6f432!important;margin-top:0;font-size:1.1rem} body.postid-1011 .mm-refs ol{padding-left:1.3rem;margin:.5em 0 0;color:#cfcfcf} body.postid-1011 .mm-refs li{margin-bottom:.5em;font-size:.9em;line-height:1.55} body.postid-1011 .mm-refs em{color:#cccccc} \/* === Mobile === *\/ @media(max-width:680px){ body.postid-1011 h1.mm-custom-title{font-size:1.55em} body.postid-1011 .mm-subtitle{font-size:.9em} body.postid-1011 .mm-content h2{font-size:1.3em} body.postid-1011 .mm-content h3{font-size:1.1em} body.postid-1011 .mm-content p{font-size:.95rem} body.postid-1011 .mm-content table{font-size:.78rem} body.postid-1011 .mm-content table th,body.postid-1011 .mm-content table td{padding:.45rem .55rem} } <\/style> <div class='mm-hero'><img src='https:\/\/menteymanzana.com\/wp-content\/uploads\/2026\/07\/glucosamina-01-hero.png' alt='C\u00e1psula de glucosamina y un cerebro anat\u00f3mico en equilibrio sobre una balanza de lat\u00f3n antigua' \/><\/div> <h1 class='mm-custom-title'><span class='accent'>GLUCOSAMINE<\/span>: THE <span class='accent'>PARADOX<\/span> ALZHEIMER&#039;S<\/h1> <p class='mm-subtitle'>A double-edged amino sugar: a shield in the healthy brain, a trigger once neurodegeneration has begun<\/p> <div class='mm-content'> <div class='mm-disclaimer'><strong>Editorial note.<\/strong> This dossier is a review of post-marketing pharmacovigilance and clinical literature on glucosamine. <strong>This does not constitute medical advice or a recommendation to discontinue any supplement on your own.<\/strong> The aggregated guidelines for the management of osteoarthritis are not altered by this analysis, and in cognitively healthy adults, previous evidence continues to point to a neutral or protective profile. The purpose is to rigorously document an emerging and specific safety signal: the interaction between this supplement and a brain that has already entered cognitive decline.<\/div> <p>For decades, Alzheimer&#039;s disease was interpreted almost exclusively as a problem of protein aggregation: beta-amyloid plaques on the outside of the neuron and tangles of hyperphosphorylated Tau protein on the inside. The limited effectiveness of drugs aimed at clearing these proteins has pushed neurobiology toward a different framework, one that reconceptualizes dementia as a <strong>systemic metabolic failure<\/strong> \u2014what some colloquially call <em>\u201ctype 3 diabetes\u201d<\/em>\u2014 in which glucose dysregulation, mitochondrial dysfunction, and chronic neuroinflammation precede cognitive decline by decades.<\/p> <p>Within this context of metabolic vulnerability, an over-the-counter supplement consumed by around <span class='mm-keyfig'>40 million adults<\/span> Only in the United States: glucosamine, an amino sugar naturally present in cartilage and routinely used to treat joint pain from osteoarthritis. Its reputation had been one of almost universal safety. A study by the <strong>University of Florida<\/strong> (UF), led by researchers <strong>Ramon Sun<\/strong> y <strong>Matt Gentry<\/strong> and published in <em>Nature Metabolism<\/em> in <strong>June 2026<\/strong>, It challenges that perception by linking its consumption, in people who already show signs of neurodegeneration, with an accelerated progression towards dementia and with an increase in mortality.<\/p> <div class='mm-callout'><strong>The essentials in three lines.<\/strong> In patients with mild cognitive impairment, regular glucosamine use was associated with a <strong>25% plus<\/strong> of progression to Alzheimer&#039;s; in established dementia, to a <strong>25% plus<\/strong> of ten-year mortality. In healthy brains, the same compound had acted as a neuroprotective agent. The molecule does not appear toxic in the abstract: it exploits a metabolic defect that only manifests itself when neurodegeneration has already begun.<\/div> <h2>Module 1 \u2014 The medical record: 65,000 medical histories<\/h2> <figure class='mm-section-img'><img src='https:\/\/menteymanzana.com\/wp-content\/uploads\/2026\/07\/glucosamina-02-modulo1-expedientes.png' alt='Archivo de expedientes m\u00e9dicos anonimizados con un frasco de suplemento sin etiqueta' \/><figcaption>The clinical finding comes from algorithmic mining of real medical records, not from a prospective trial.<\/figcaption><\/figure> <h3>Data mining instead of trials<\/h3> <p>To circumvent the ethical dilemmas of administering a suspect compound to frail patients, the team did not resort to a prospective trial, but rather to advanced real-world data mining. Using artificial intelligence and natural language processing algorithms, they retrospectively analyzed the electronic health records (EHRs) of the system. <strong>UF Health<\/strong> between <strong>2012 and 2024<\/strong>, extracting information from both clinical notes and prescription and supplementation records.<\/p> <p>The study encompassed more than <span class='mm-keyfig'>65,000 patients<\/span> distributed into two cohorts. The first brought together <span class='mm-keyfig'>41.884<\/span> people with <strong>Mild Cognitive Impairment<\/strong> (MCI), a prodromal state in which progression to dementia is not inevitable and a percentage of patients remain stable for years. The second encompassed <span class='mm-keyfig'>24.481<\/span> patients with <strong>Alzheimer&#039;s disease and related dementias<\/strong> (ADRD), that is, brains with already active degeneration. In both groups, close to the <span class='mm-keyfig'>8%<\/span> maintained a documented glucosamine regimen: <span class='mm-keyfig'>2.750<\/span> patients in the MCI group and <span class='mm-keyfig'>1.896<\/span> in the ADRD group. Extrapolating that prevalence to the nearly 7 million Americans living with Alzheimer&#039;s, the authors estimate that between <strong>half a million and one million<\/strong> vulnerable patients may be consuming the compound.<\/p> <h3>Divergent trajectories based on prior damage<\/h3> <p>With 5- and 10-year survival analysis models, adjusted for age, biological sex, and other demographic covariates, and a mean follow-up of <span class='mm-keyfig'>1,835 days<\/span>, The results depended on the degree of pre-existing brain damage. Among patients with mild cognitive impairment (MCI), regular glucosamine use was associated with an increase in <span class='mm-keyfig'>25%<\/span> in the probability of progressing to a diagnosis of Alzheimer&#039;s type dementia (<span class='mm-keyfig'>P &lt; 0.001<\/span>). In the cohort with established dementia, exposure was associated with an increase in <span class='mm-keyfig'>25%<\/span> in the risk of all-cause mortality over ten years (<span class='mm-keyfig'>P = 0.0023<\/span>).<\/p> <p>The most revealing piece of information from a biological point of view was a <em>absence<\/em>: glucosamine <strong>No<\/strong> significantly altered mortality in the MCI group (<span class='mm-keyfig'>P = 0.252<\/span>This lack of lethality in the prodromal stage suggests that the compound does not act as a universal toxin that indiscriminately kills neurons, but rather exacerbates a metabolic defect that is fully expressed only when neuronal networks have already entered a phase of active degeneration.<\/p> <table> <thead><tr><th>Cohort<\/th><th>Patients<\/th><th>Use of glucosamine<\/th><th>Progression to dementia<\/th><th>Mortality (10 years)<\/th><\/tr><\/thead> <tbody> <tr><td><strong>Mild Cognitive Impairment (MCI)<\/strong><\/td><td>41.884<\/td><td>2.750 (8,0%)<\/td><td>+25% (P &lt; 0.001)<\/td><td>No difference (P = 0.252)<\/td><\/tr> <tr><td><strong>Alzheimer&#039;s and Dementia (ADRD)<\/strong><\/td><td>24.481<\/td><td>1.896 (7,7%)<\/td><td>Not applicable (already established)<\/td><td>+25% (P = 0.0023)<\/td><\/tr> <\/tbody> <\/table> <p><em>Table 1. Longitudinal dynamics of the impact of glucosamine supplementation extracted from UF Health electronic medical records.<\/em><\/p> <h2>Module 2 \u2014 The molecular machinery: from sugar to synaptic damage<\/h2> <figure class='mm-section-img'><img src='https:\/\/menteymanzana.com\/wp-content\/uploads\/2026\/07\/glucosamina-03-modulo2-moleculas.png' alt='Visualizaci\u00f3n microsc\u00f3pica de mol\u00e9culas de az\u00facar cruzando la barrera hematoencef\u00e1lica' \/><figcaption>Glucosamine crosses the blood-brain barrier via glucose transporters and overloads the glycosylation machinery.<\/figcaption><\/figure> <h3>How it gets in: the blood-brain barrier<\/h3> <p>To influence the brain, glucosamine must first cross the blood-brain barrier, and as a polar molecule, it is entirely dependent on glucose transporters (GLUT family). <strong>GLUT1<\/strong> It acts as a sentinel of the barrier. Once inside, the astrocytes use the <strong>GLUT2<\/strong>, which despite having a low affinity for glucose shows an exceptional affinity for glucosamine (<span class='mm-keyfig'>Km = 0.8 mM<\/span>), and the neurons resort to <strong>GLUT3<\/strong>, the one with the greatest transport capacity. The result is that, when blood concentrations rise after supplementation, the amino sugar is massively internalized into nerve tissue.<\/p> <h3>The metabolic shunt: the hexosamine pathway<\/h3> <p>Within the neuron, the fate of glucosamine differs from that of glucose. Under normal conditions, only between the <span class='mm-keyfig'>2% and 5%<\/span> glucose is diverted to <strong>Hexosamine Biosynthesis Pathway<\/strong> (HBP), whose entry is strictly controlled by the rate-limiting enzyme GFAT. The problem is that exogenous glucosamine, when directly phosphorylated by hexokinase, <strong>completely bypasses that checkpoint<\/strong> and floods the pathway with unlimited substrate, forcing the overproduction of <em>UDP-GlcNAc<\/em>, the universal donor of sugars for cellular glycosylation.<\/p> <h3>The hyperglycosylation signature<\/h3> <p>To see that excess in the tissue, Sun&#039;s lab applied imaging mass spectrometry (<em>MALDI-MSI<\/em>), optimized with iterative xylene washes that multiplied between <span class='mm-keyfig'>10 and 20 times<\/span> the N-glycan signal. The result was an unmistakable signature in the frontal cortex of Alzheimer&#039;s patients compared to age-matched controls: a <strong>massive hyperglycosylation<\/strong>, with a high abundance of high mannose glycans (species <em>m\/z<\/em> 1.419, 1.581 and 1.905) and bisecting (<em>m\/z<\/em> 1,688) in the cortex, hippocampus, and thalamus. And critically, the concentration of these sugars escalated in direct proportion to the severity of the damage, as measured by the <strong>Braak stadium<\/strong>. Isotopic tracing confirmed that the excess came from overactive biosynthesis, not from a failure in depuration.<\/p> <p>More than <span class='mm-keyfig'>90\u201395%<\/span> The affected glycoproteins are the same as in a healthy brain: the defect is not in <em>that<\/em> The proteins themselves are modified, but the magnitude of the labeling is affected. This excess destabilizes the networks involved in the disease. It alters the trafficking of the <strong>amyloid precursor protein<\/strong> (APP), diverting it towards compartments rich in the enzyme <em>BACE1<\/em> and favoring the amyloidogenic pathway that generates plaques; it aggravates the dissociation of <strong>Tau<\/strong> of microtubules; and compromises ion channels and vesicle recycling, progressively silencing neuronal communication. In mouse models (<em>5xFAD<\/em> y <em>PS19<\/em>), silencing glycosylation enzymes restored memory, while administering oral glucosamine exacerbated deficits to the point of near-total failure on social recognition tests.<\/p> <h2>Module 3 \u2014 The paradox: a shield in the healthy, a trigger in the sick<\/h2> <figure class='mm-section-img'><img src='https:\/\/menteymanzana.com\/wp-content\/uploads\/2026\/07\/glucosamina-04-modulo3-paradoja.png' alt='Dos viales de laboratorio id\u00e9nticos con soluciones de destinos opuestos' \/><figcaption>The same molecule, two opposite fates depending on the metabolic state of the brain that receives it.<\/figcaption><\/figure> <h3>The support of the UK Biobank<\/h3> <p>The revelation clashes with a body of previous literature that argued precisely the opposite. The analyses of <strong>UK Biobank<\/strong> \u2014a prospective study of more than <span class='mm-keyfig'>500,000 participants<\/span> British researchers, using strict exclusion criteria to eliminate baseline dementia, had associated glucosamine with a reduced risk of dementia in healthy individuals. Using propensity score matching (<span class='mm-keyfig'>52.525<\/span> users versus an equal number of non-users) and Cox models with tracking <span class='mm-keyfig'>8.9 to 13.8 years<\/span>, The data showed a lower risk of major dementias.<\/p> <table> <thead><tr><th>Neurodegenerative condition<\/th><th>Hazard Ratio (HR)<\/th><th>IC 95%<\/th><th>Risk reduction<\/th><\/tr><\/thead> <tbody> <tr><td><strong>Dementia from all causes<\/strong><\/td><td>0,84<\/td><td>0,75 \u2013 0,93<\/td><td>16% less<\/td><\/tr> <tr><td><strong>Alzheimer&#039;s disease<\/strong><\/td><td>0,83<\/td><td>0,71 \u2013 0,98<\/td><td>17% less<\/td><\/tr> <tr><td><strong>Vascular dementia<\/strong><\/td><td>0,74<\/td><td>0,58 \u2013 0,95<\/td><td>26% minor<\/td><\/tr> <\/tbody> <\/table> <p><em>Table 2. UK Biobank data (prior to 2026) in cognitively intact adults at baseline.<\/em><\/p> <p>The protective phenotype extended to all-cause and cardiovascular mortality (reductions of between the <span class='mm-keyfig'>15% and 39%<\/span>), and a design of <strong>Mendelian randomization<\/strong> This suggested that the protection was not merely an artifact of the &quot;healthy user.&quot; As a side note, the supplement appeared to increase the risk of atrial fibrillation by a certain amount. <span class='mm-keyfig'>51%<\/span> in those under 65 years of age, which already suggested a phenotype-dependent response.<\/p> <h3>Caloric restriction mimicry<\/h3> <p>Sun and Gentry resolve the paradox with a framework of <strong>homeostatic differentiation<\/strong>. In the healthy brain, with intact metabolic buffering systems, glucosamine primarily induces cytoplasmic modifications (<em>O-GlcNAcylation<\/em>) with anti-inflammatory effect \u2014suppresses the pathway <em>NF-\u03baB<\/em>\u2014 and acts almost like a <strong>calorie restriction mimetic<\/strong>, prolonging cell life. In the Alzheimer&#039;s brain, however, metabolic resilience has collapsed and the sugar-labeling system is permanently activated. Providing glucosamine at that point, in the authors&#039; words, is equivalent to <strong>to throw fuel on a molecular fire<\/strong>The substrate evades the controls and floods an irreversibly hyperactive hexosamine pathway.<\/p> <h3>Criticism: cause or shadow?<\/h3> <p>The epidemiological component received notable resistance from the industry. <strong>Dr. Daniel Fabricant<\/strong>, of the <strong>Natural Products Association<\/strong> (NPA), and the <strong>Dr. Jacob Teitelbaum<\/strong> They pointed out a possible confounding bias. Those who take glucosamine usually do so for painful osteoarthritis, and the <strong>chronic pain<\/strong> is independently associated with up to one <span class='mm-keyfig'>43% plus<\/span> risk of dementia due to the sustained allostatic stress it generates. Under that interpretation, the glucosamine recorded in the records would be a <em>proxy<\/em> of the underlying damage, not its cause. The NPA adds that the model also failed to adjust for the ultra-processed diet or the <strong>advanced glycation end products<\/strong> (AGEs), abundant in this population. Sun acknowledged the need for trials, but ruled out administering the compound to patients after detecting the mortality signal; his laboratory proposes instead a <em>\u201crandomized withdrawal trial\u201d<\/em>, to discontinue the supplement in users with MCI to measure whether it slows the decline slope.<\/p> <h2>Module 4 \u2014 The gut-brain axis: the systemic root<\/h2> <figure class='mm-section-img'><img src='https:\/\/menteymanzana.com\/wp-content\/uploads\/2026\/07\/glucosamina-05-modulo4-intestino.png' alt='Visualizaci\u00f3n anat\u00f3mica del eje intestino-cerebro con se\u00f1ales inflamatorias' \/><figcaption>Neuropathology is, in part, the final stage of an inflammatory process that starts in the intestine.<\/figcaption><\/figure> <h3>From dysbiosis to neuroinflammation<\/h3> <p>The damage observed in the cortex is, to a large extent, the terminal phase of a peripheral process that begins in the gut. The metabolic syndromes that precede dementia\u2014obesity, insulin resistance, dyslipidemia\u2014generate <strong>dysbiosis<\/strong>The synthesis of <strong>short-chain fatty acids<\/strong> (SCFAs, such as butyrate and propionate), essential to maintain the integrity of both the intestinal epithelium and the blood-brain barrier itself.<\/p> <p>With the erosion of that epithelium (<em>leaky gut<\/em>), the <strong>lipopolysaccharides<\/strong> (LPS) from gram-negative bacteria translocate into the circulation and trigger a <strong>metabolic endotoxemia<\/strong> low-grade. That surge of LPS chronically activates the receptors. <em>TLR4<\/em> and the way <em>NF-\u03baB<\/em>, releasing cytokines \u2014<em>IL-1\u03b2<\/em>, <em>IL-6<\/em> y <em>TNF-\u03b1<\/em>\u2014which penetrate an already weakened barrier and inflame the microglia. In that environment, protective genes such as <strong>TREM2<\/strong> They are inhibited, reducing the glial cells&#039; ability to clear amyloid. When glucosamine enters this pro-inflammatory scenario, the metabolic buffer fails and the dual storm is triggered: central inflammation combined with proteotoxic hyperglycosylation.<\/p> <h2>Balance \/ Conclusions<\/h2> <p><strong>First<\/strong>, The finding describes a <em>dependence<\/em>, not a universal toxicity. Glucosamine did not increase mortality in the early stages of mild cognitive impairment (MCI), but it did accelerate progression and mortality once neurodegeneration was active. The damage depends on the metabolic environment it encounters.<\/p> <p><strong>Second<\/strong>, The mechanistic plausibility is strong. Spatial omics documented the hyperglycosylation signature scaling with the Braak stage, and mouse experiments showed causality in both directions: silencing glycosylation restored memory; adding glucosamine impaired it.<\/p> <p><strong>Third<\/strong>, However, the limitations are real and should not be minimized. The epidemiological arm is retrospective and did not adjust for significant variables such as chronic pain or dietary AGE burden. Causality in humans has not been demonstrated and remains pending the proposed withdrawal trial.<\/p> <p><strong>Room<\/strong>, The practical interpretation is one of caution. In cognitively healthy adults, the available evidence continues to lean toward a neutral or protective profile. In individuals with mild cognitive impairment or established dementia, the risk-benefit balance changes, and any decision regarding supplementation should be made under medical supervision. This dossier documents a safety signal; it does not issue a verdict.<\/p> <div class='mm-refs'><h3>Selected references<\/h3><ol> <li>Sun R, Gentry M, et al. (2026). <em>Hyper-Glycosylation as a Central Metabolic Driver of Alzheimer&#039;s Disease.<\/em> Nature Metabolism (bioRxiv preprint\/PubMed 40654813).<\/li> <li>Ma H, et al. (2023). <em>Association of regular glucosamine use with incident dementia: evidence from a longitudinal cohort and Mendelian randomized study.<\/em> BMC Medicine (PMC10052856).<\/li> <li>Li Z, et al. (2023). <em>Habitual glucosamine use, APOE genotypes, and risk of incident cause-specific dementia in the older population.<\/em> (PMC10492372).<\/li> <li>Szablewski L. (2021). <em>Brain Glucose Transporters: Role in Pathogenesis and Potential Targets for the Treatment of Alzheimer&#039;s Disease.<\/em> (PMC8348194).<\/li> <li>Koepsell H. (2020). <em>Glucose transporters in brain in health and disease.<\/em> Pfl\u00fcgers Archive (PMC7462931).<\/li> <li>Conroy LR, et al. (2021). <em>Emerging roles of N-linked glycosylation in brain physiology and disorders.<\/em> (PMC8589112).<\/li> <li>Kizuka Y, et al. (2022). <em>In situ spatial glycomic imaging of mouse and human Alzheimer&#039;s disease brains.<\/em> (PMC9198106).<\/li> <li>Frontiers in Aging Neuroscience (2025). <em>Integrated analysis of N-glycosylation and Alzheimer&#039;s disease: identifying key biomarkers and mechanisms.<\/em> doi:10.3389\/fnagi.2025.1597511.<\/li> <li>PMC (2021). <em>Glucosamine and Its Analogues as Modulators of Amyloid-\u03b2 Toxicity.<\/em> (PMC8040036).<\/li> <li>PMC (2023). <em>Unlocking the Sugar Code: Implications and Consequences of Glycosylation in Alzheimer&#039;s Disease and Other Tauopathies.<\/em> (PMC12730515).<\/li> <li>PMC. <em>The impact of nutritional and exercise interventions on Alzheimer&#039;s disease pathophysiology via modulation of the microbiota-gut-brain-axis.<\/em> (PMC12643020).<\/li> <li>PMC (2019). <em>The gut microbiota to the brain axis in the metabolic control.<\/em> (PMC6938794).<\/li> <li>Vitamin Retailer (2026). <em>Industry Criticizes Study on Glucosamine Supplements and Alzheimer&#039;s Disease.<\/em><\/li> <li>Natural Products Association (2026). <em>NPA Responds To Study On Glucosamine Supplements, Alzheimer&#039;s.<\/em><\/li> <li>University of Florida News (2026). <em>Study links joint pain supplement to accelerating dementia.<\/em> UF Health.<\/li> <\/ol><\/div> <\/div>","protected":false},"excerpt":{"rendered":"<p>GLUCOSAMINA: LA PARADOJA DEL ALZHEIMER Un aminoaz\u00facar de doble filo: escudo en el cerebro sano, detonante una vez iniciada la neurodegeneraci\u00f3n Nota editorial. Este dossier es una revisi\u00f3n de farmacovigilancia post-comercializaci\u00f3n y literatura cl\u00ednica sobre la glucosamina. No constituye consejo m\u00e9dico ni una recomendaci\u00f3n de suspender ning\u00fan suplemento por cuenta propia. Las pautas agregadas para [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1013,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[51,45],"tags":[],"class_list":["post-1011","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-longevidad-metricas","category-noticias"],"acf":{"hallazgo_clave":"En cerebros ya enfermos, la glucosamina se asoci\u00f3 a +25% de progresi\u00f3n a demencia y +25% de mortalidad a 10 a\u00f1os.","tiempo_lectura":12,"nivel_evidencia":"alto","fuente_original":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40654813\/","protocolo_aplicable":false,"referencias_texto":"","tags_cientificos":"glucosamina, hiperglicosilaci\u00f3n, UDP-GlcNAc, barrera hematoencef\u00e1lica, transportadores GLUT, v\u00eda de las hexosaminas, N-glicosilaci\u00f3n, Alzheimer, deterioro cognitivo leve, eje intestino-cerebro, farmacovigilancia, UK Biobank"},"hallazgo_clave":"En cerebros ya enfermos, la glucosamina se asoci\u00f3 a +25% de progresi\u00f3n a demencia y +25% de mortalidad a 10 a\u00f1os.","tiempo_lectura":"12","nivel_evidencia":"alto","fuente_original":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40654813\/","protocolo_aplicable":false,"referencias_texto":null,"tags_cientificos":"glucosamina, hiperglicosilaci\u00f3n, UDP-GlcNAc, barrera hematoencef\u00e1lica, transportadores GLUT, v\u00eda de las hexosaminas, N-glicosilaci\u00f3n, Alzheimer, deterioro cognitivo leve, eje intestino-cerebro, farmacovigilancia, UK Biobank","_links":{"self":[{"href":"https:\/\/menteymanzana.com\/en\/wp-json\/wp\/v2\/posts\/1011","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/menteymanzana.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/menteymanzana.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/menteymanzana.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/menteymanzana.com\/en\/wp-json\/wp\/v2\/comments?post=1011"}],"version-history":[{"count":2,"href":"https:\/\/menteymanzana.com\/en\/wp-json\/wp\/v2\/posts\/1011\/revisions"}],"predecessor-version":[{"id":1018,"href":"https:\/\/menteymanzana.com\/en\/wp-json\/wp\/v2\/posts\/1011\/revisions\/1018"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/menteymanzana.com\/en\/wp-json\/wp\/v2\/media\/1013"}],"wp:attachment":[{"href":"https:\/\/menteymanzana.com\/en\/wp-json\/wp\/v2\/media?parent=1011"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/menteymanzana.com\/en\/wp-json\/wp\/v2\/categories?post=1011"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/menteymanzana.com\/en\/wp-json\/wp\/v2\/tags?post=1011"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}